ArticleInfection and drug resistance2026
High-Resolution Melting Curve Analysis (HRMA) for the Identification of Class D β-Lactamases (CHDLs) in
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Conventional approaches for laboratory detection of Carbapenem-hydrolyzing class D β-lactamases (CHDLs) from clinical isolates of Methods: Detection of Results: Out of the 47 Conclusion: Novelty lies in the precise differentiation of six clinically relevant OXA alleles exclusively through unique melting temperature (Tm) shifts and melt curve morphologies, eliminating the need for fluorescent probes. In practice, HRMA offers significant advantages over conventional methods, such as the modified Hodge test or Sanger sequencing. As a closed-tube, single-step assay, it eliminates post-amplification handling, reduces cross-contamination risks, and provides actionable results within two hours. This marked reduction in turnaround time and reagent costs makes HRMA a highly scalable, user-friendly tool, ideally suited for routine clinical microbiology laboratories to expedite antimicrobial stewardship and epidemiological surveillance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.